Nivolumab-induced immune mediated eczematous dermatitis in patient with carcinoma of buccal mucosa
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20233909Keywords:
Nivolumab, Eczematous dermatitis, Immune-related adverse eventAbstract
An elderly man undergoing treatment for carcinoma of left buccal mucosa experienced the appearance of skin lesions on his chest, both upper limbs, and both lower limbs after receiving the first cycle of nivolumab therapy. A biopsy report confirmed that the patient had eczematous dermatitis, which was believed to be induced by nivolumab. Patient received symptomatic treatment with Prednisolone, Clobetasol propionate and Fusidic acid. The Skin lesions improved, and subsequently Framycetin cream was recommended, resulting in no further recurrence of lesion. Clinicians should remain vigilant about development of T-cell activation-related skin disorders when administrating immune checkpoint inhibitors, such as nivolumab.
References
Wellstein A, Giaccone G, Atkins MB, Sausville EA. In: Brunton LL, Hilal-Dandan R, Knollman BC. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th edition. New York: Mc Graw Hill Education. 2023;863-85.
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol. 2018;8:86.
Nguyen ED, Xue YK, Danesh M, Ameri A, Weng CQ, Klebanov N, et al. A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies. Dermatopathology (Basel). 2020;6(4):255-9.
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345-61.
Patel AB, Pacha O. Skin reactions to immune checkpoint inhibitors. Adv Exp Med Biol. 2018;995:117-29.
Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol. 2016;74(3):455-61.
Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12-25.
